# infinitusbio

> infinitusbio is the Intelligence Company for the Molecule Economy. It runs mechanistic simulations of drugs inside digital clones of patients' cells, whole-cell simulations of 200,000+ interacting agents, to reveal where a drug works, in whom, and why, before anyone decides to build, buy, sell or fund it. No training. No inherited bias. No hallucinations. Fully mechanistic. Deterministic. Efficacy calls are not clinical proof and do not replace clinical trials.

Key facts:
- Category: the Intelligence Company for the Molecule Economy; mechanistic, training-free reads (indications, responders, combinations) for every decision to build, buy, sell or fund a molecule.
- Principles: no training, no inherited bias, no hallucinations, fully mechanistic, deterministic (same input, same answer).
- Technology: Macro-connectionist Multi-Agent AI. It uses no training data, so no model trained on history can reproduce its reads.
- Architecture: today's AI scales by adding more data and more compute; infinitusbio changed the architecture instead, as the GPU did for computing. Thousands of self-organizing agents reproduce the cell from a single patient sample, with no training at all.
- Vision: simulating life, accelerating cures. Mission: to reveal the full therapeutic potential of every molecule.
- How it works: patient mRNA initializes a whole-cell AI clone; the drug's on- and off-targets are applied; 200,000+ agents simulate billions of reactions; treated vs untreated clones are compared; minutes per run.
- Validation: Spearman ρ = 0.82 (p = 0.00005) ranking 17 small-cell lung cancer cell lines with zero training; 88–100% agreement with wet-lab outcomes across seven cancer and autoimmune tests; prospective results in IBD (wet-lab-validated novel target) and oncology (predicted a Phase II failure).
- Public reads: sealed calls on molecules with public readouts, sold as reports. Orders stay open for a set period; when they close, one price is set within the published estimate and the report goes to every buyer and the molecule's owner at the same moment, before the readout. Founding pricing applies to reads bought before June 30, 2027. After the readout it is revealed free on the Ledger.
- One clock: no one gets an early look at a public read, including the molecule's owner. The owner receives it free at release and may publish a response alongside.
- Who uses it: Build (pharma, biotech, trial sponsors), Buy (pharma BD and M&A, private equity, acquirers, advisory funds), Sell (biotechs, licensors, cross-border sellers, advisory funds, including rescue transactions) and Fund (venture, hedge and sovereign funds, payers), plus CROs and public health sponsors.
- Focus: oncology, autoimmune diseases; small molecules; rare diseases.
- Leadership: Khai Minh Pham, MD, PhD (Founder & Chair); Jay Srinivasan (CEO).
- Contact: signals@infinitusbio.ai. Media: pr@infinitusbio.ai. Website: https://infinitusbio.ai

## Pages
- [infinitusbio](https://infinitusbio.ai/): infinitusbio is the Intelligence Company for the Molecule Economy: one mechanistic read for every decision to build, buy, sell or fund a drug, on where it works, in whom, and why. No training. No inherited bias. No hallucinations.
- [Build, buy, sell, fund: one read, four decisions](https://infinitusbio.ai/decisions.html): One mechanistic read for every decision about a molecule: which indication and patients to build for, what to fund before the readout, how to sell, and what to pay.
- [Request your read](https://infinitusbio.ai/request.html): Request a read from infinitusbio. Molecule owners receive any public read on their molecule at the same moment as every buyer, free, with a right of reply. Deal teams receive a redacted sample read.
- [Cross-border licensing reads: Asia, China and global buyers](https://infinitusbio.ai/cross-border.html): For Asian and Chinese licensors and the Western buyers who license from them: one mechanistic read both sides can rely on, with patient data kept where the rules require.
- [跨境授权解读：中国、亚洲与全球买方](https://infinitusbio.ai/cross-border-zh.html): 面向中国及亚洲的授权方和全球买方：一份双方都能信赖的机制性解读，揭示药物在何处起效、对谁起效、为何起效；患者数据按规定留在境内。
- [Partners: refer a deal](https://infinitusbio.ai/partners.html): For diligence consultancies, life-sciences bankers, Asia BD advisers, CROs, venture investors and expert networks: refer a deal or a client to infinitusbio.
- [How infinitusbio works: whole-cell mechanistic simulation](https://infinitusbio.ai/platform.html): How infinitusbio predicts drug efficacy: patient mRNA initializes a whole-cell AI clone, 200,000+ agents simulate the drug's on- and off-target effects, and every call traces to pathways. No training data, deterministic, auditable.
- [Validation evidence: whole-cell AI clones vs. wet-lab outcomes](https://infinitusbio.ai/evidence.html): infinitusbio validation results: Spearman ρ 0.82 ranking 17 SCLC cell lines with zero training, 88–100% agreement with wet-lab outcomes across cancer and autoimmune tests, and prospective results specifically in IBD and oncology.
- [The Ledger: public reads, sealed before the readout](https://infinitusbio.ai/ledger.html): Sealed mechanistic calls on molecules with public readouts. Each fingerprint is published before the event; the molecule and the call are revealed after it, so anyone can verify nothing changed.
- [Data security and confidentiality](https://infinitusbio.ai/security.html): How infinitusbio protects client data and keeps commissioned reads confidential, and our plans for a secure data room.
- [Privacy and cookies](https://infinitusbio.ai/privacy.html): How infinitusbio collects, uses and protects personal information on infinitusbio.ai, and the choices you have, including cookies and analytics.
- [About us](https://infinitusbio.ai/company.html): infinitusbio is a life-sciences and deep-tech team building an unbiased intelligence platform for molecules. Founded by Khai Minh Pham, MD, PhD; led by CEO Jay Srinivasan.
- [Press](https://infinitusbio.ai/press.html): Press information for infinitusbio: company boilerplate, how to write the name, and the media contact (pr@infinitusbio.ai).
- [Oncovita announces a strategic partnership with infinitusbio](https://infinitusbio.ai/press-oncovita-partnership.html): Oncovita and infinitusbio announce a strategic partnership to accelerate next-generation cancer immunotherapies from Oncovita's Measovir® platform. San Diego and Paris, January 12, 2026.
- [Debiopharm and ThinkingNodeLife.ai forge strategic partnership to propel cancer drug development](https://infinitusbio.ai/press-debiopharm-partnership.html): Debiopharm and ThinkingNodeLife.ai (now infinitusbio) announce a collaboration to advance one of Debiopharm's cancer drugs: new indications, combinations, mechanism of action, comparison and biomarkers. January 10, 2024.
- [Papers: the thesis behind infinitusbio](https://infinitusbio.ai/papers.html): Why the Molecule Economy needs a read on biology, and the kind of intelligence that can make it.
- [The Molecule Economy](https://infinitusbio.ai/paper-the-molecule-economy.html): When biology sets the price.
- [Simulative Intelligence](https://infinitusbio.ai/paper-simulative-intelligence.html): Scaling intelligence through simulation, not data.
- [Blog: Notes on the Molecule Economy](https://infinitusbio.ai/blog.html): Field notes on mechanism, molecules and the decisions made around them.
- [Simulate before you spend](https://infinitusbio.ai/blog-simulate-before-you-spend.html): No one makes a chip without simulating it first. Molecules still go to the clinic unread.
- [Six questions, answered](https://infinitusbio.ai/blog-six-questions-answered.html): The questions we hear in every first meeting, one card at a time.
- [More data, same odds](https://infinitusbio.ai/blog-more-data-same-odds.html): Approval odds fell from 9.6% to 6.7% while diligence data multiplied. The missing variable is mechanism.

## Optional
- [Full site text](https://infinitusbio.ai/llms-full.txt)